Company profile for Antag Therapeutic

Antag Therapeutic

NEW Drugs in Dev: 1

Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Contact Supplier

Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

Contact Supplier

Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

Contact Supplier

Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

pharmacompass-2-2026-02-09

Contact Supplier

VIRTUAL BOOTH
CONTACT DETAILS
Google Map, LinkedIn, Emails...

DIGITAL CONTENT

6 News #PharmaBuzz

media
6 News #PharmaBuzz

DEVELOPMENTS

4 Drugs in Development

4 Drugs in Development

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Antag Therapeutics is a biotech company specializing in the development of therapeutic peptides that modulate GIP biology. Their research focuses on addressing obesity and cardiovascular autonomic diseases, such as postural orthostatic tachycardia syndrome (POTS). Built on decades of scientific research from the University of Copenhagen, Antag’s peptides are optimized analogues of natural inhibitors of the GIP receptor. Thei...

Antag Therapeutics is a biotech company specializing in the development of therapeutic peptides that modulate GIP biology. Their research focuses on addressing obesity and cardiovascular autonomic diseases, such as postural orthostatic tachycardia syndrome (POTS). Built on decades of scientific research from the University of Copenhagen, Antag’s peptides are optimized analogues of natural inhibitors of the GIP receptor. Their lead product, AT-7687, aims to provide new treatment options for patients suffering from these complex conditions.

Clinical OutsourcingClinical Outsourcing

Not Confirmed

Not Confirmed

03-04 March, 2026

Copthorne Tara Hotel, London Kensington, United Ki
Natural Product Expo W...Natural Product Expo West

Not Confirmed

Not Confirmed

03-06 March, 2026

California, U.S.A
Natural Products ExpoNatural Products Expo

Not Confirmed

Not Confirmed

03-06 March, 2026

California, U.S.A

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown

Country

Country

Denmark

Address

Address

COBIS Ole Maaløes Vej 3 2200 Copenhagen

Telephone

Telephone

Email

enquiries@pharmacompass.com

Client Website

Website

https://antagtherapeutics.com/

Linkedin

youtube

YouTube

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

Antag Therapeutics Shows Promising GIPR Antagonist For Obesity

08 Jan 2026

// GLOBENEWSWIRE

Antag Therapeutics starts Ph 1a trial of AT-7687, GIPR Antagonist

02 Apr 2025

// GLOBENEWSWIRE

Antag Therapeutics Announces €80 Million Series A Financing

04 Dec 2024

// PR NEWSWIRE

Antag secures $84M series A for GLP-1 add-on

04 Dec 2024

// FIERCE BIOTECH

Antag Therapeutics Announces FDA Clearance For IND Application

09 Oct 2024

// PR NEWSWIRE

Antag Therapeutics appoints Dr. Christine T. Fischette to its Board of Directors

15 Jul 2021

// PR NEWSWIRE

Drugs in Development

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Market Place

Home

Menu

Post Enquiry

Market Place

Search